ImmunoGen, Inc. Announces Election of Howard Pien to its Board of Directors & Other Results from its Annual Meeting of Shareh...
November 11 2009 - 12:45PM
Business Wire
ImmunoGen, Inc. (Nasdaq:
IMGN), a biotechnology company that develops targeted anticancer
products, announced that Howard Pien was elected to its Board of
Directors at today’s Annual Meeting of Shareholders. The Company
also announced that Stephen C. McCluski has been named Chairman of
the Board, replacing former ImmunoGen CEO Mitchel Sayare, Ph.D., in
this position. Dr. Sayare continues to serve on the Board as a
director.
“We believe now is an appropriate time to realign our corporate
governance structure and have a non-executive chairman,” commented
Daniel Junius, ImmunoGen President and CEO. “Steve has demonstrated
that he can be an effective leader of the Board, and I look forward
to working with him and the other directors in continuing to move
the Company forward.”
Mr. McCluski has served on the ImmunoGen Board of Directors
since April 2007, bringing to it extensive business and financial
expertise. He was the Senior Vice President and Chief Financial
Officer of Bausch & Lomb Inc. prior to his retirement in 2007.
Mr. McCluski is also a director of the James P. Wilmot Cancer
Center of the University of Rochester and of Standard Microsystems
Corporation.
“I look forward to serving ImmunoGen as chairman and – in this
capacity – I am delighted to welcome Howard to the Board,”
commented Mr. McCluski. “Howard’s experience at successful
biotechnology and pharmaceutical companies will be invaluable as
ImmunoGen continues to advance its pipeline.”
Mr. Pien was the Chairman of the Board and CEO of
Medarex, Inc. from 2007 to its acquisition by Bristol-Myers
Squibb Company in September 2009. Prior to that, he was President
and CEO of Chiron Corporation from 2003 to its acquisition by
Novartis, and before that Mr. Pien held positions of increasing
responsibility at GlaxoSmithKline and its predecessor, SmithKline
Beecham, at Abbott Laboratories and at Merck & Co. He is also a
director of ViroPharma Incorporated and Vanda Pharmaceuticals.
“ImmunoGen is transitioning to becoming an organization that not
only does outstanding research but also successfully advances
significant new anticancer therapeutics, and I am looking forward
to serving on its Board,” commented Mr. Pien.
At today’s Annual Meeting, shareholders also voted to fix the
number of members of the Board of Directors at nine and approved an
amendment to the Company's restated articles of organization
to increase the number of authorized shares of common stock
from 75 million to 100 million shares. In addition to electing
Mr. Pien and re-electing Mr. McCluski and Dr. Sayare to the Board,
shareholders re-elected Mr. Daniel Junius, Mr. David Carter, Dr.
Nicole Onetto, Mr. Mark Skaletsky, Dr. Joseph Villafranca and
Mr. Richard Wallace to the Board.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s proprietary cell-killing
agents specifically to cancer targets. In addition to the Company’s
product pipeline, compounds utilizing the TAP technology are in
clinical testing through ImmunoGen’s collaborations with Genentech
(a wholly-owned member of the Roche Group), sanofi-aventis, Biogen
Idec and Biotest. The most advanced compound, trastuzumab-DM1
(T-DM1), is in Phase III testing being conducted by Genentech
and Roche. Other ImmunoGen collaborative partners include Bayer
HealthCare and Amgen. More information about ImmunoGen can be found
at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024